Galapagos: A Split Should Finally Lead the Company out of No Man's Land

Galapagos suffered a severe setback in August 2020 and has largely been off the radar since then. The Belgian biopharmaceutical company had entered into a close partnership with Gilead Sciences in 2019 to develop Filgotinib. For this, Galapagos received an upfront payment of nearly $4 billion. FDA rejection led to total collapse of the company and the stock Under the trade name Jyseleca, the drug has been launched in the EU, the UK, and Japan in recent years. However, the major breakthrough was expected to be the approval in the USA. Nevertheless,...